CN110621302A - 结合肌生成抑制蛋白的纤连蛋白基支架结构域蛋白质的稳定制剂 - Google Patents
结合肌生成抑制蛋白的纤连蛋白基支架结构域蛋白质的稳定制剂 Download PDFInfo
- Publication number
- CN110621302A CN110621302A CN201880029635.0A CN201880029635A CN110621302A CN 110621302 A CN110621302 A CN 110621302A CN 201880029635 A CN201880029635 A CN 201880029635A CN 110621302 A CN110621302 A CN 110621302A
- Authority
- CN
- China
- Prior art keywords
- formulation
- myostatin
- polypeptide
- domain
- adnectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500649P | 2017-05-03 | 2017-05-03 | |
| US62/500,649 | 2017-05-03 | ||
| PCT/US2018/030851 WO2018204617A1 (en) | 2017-05-03 | 2018-05-03 | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110621302A true CN110621302A (zh) | 2019-12-27 |
Family
ID=62223280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880029635.0A Pending CN110621302A (zh) | 2017-05-03 | 2018-05-03 | 结合肌生成抑制蛋白的纤连蛋白基支架结构域蛋白质的稳定制剂 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200129595A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3618809A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7157082B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102838263B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110621302A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018261154B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3062797A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL270233B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012506A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909709SA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI897843B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018204617A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
| CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
| TW202432577A (zh) * | 2023-02-10 | 2024-08-16 | 美商拜奧海芬治療學有限公司 | 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀 |
| WO2025177263A1 (en) * | 2024-02-25 | 2025-08-28 | Biohaven Therapeutics Ltd. | Myostatin-binding proteins |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102007145A (zh) * | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| CN102099373A (zh) * | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
| CN102762591A (zh) * | 2010-02-18 | 2012-10-31 | 百时美施贵宝公司 | 结合il-23的基于纤连蛋白的支架结构域蛋白质 |
| CN103180339A (zh) * | 2010-05-26 | 2013-06-26 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
| CN104768969A (zh) * | 2012-09-13 | 2015-07-08 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子(vegf)−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| US20030191187A1 (en) * | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| AU2008345424A1 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| CN102076713B (zh) | 2008-05-02 | 2015-03-25 | 诺华股份有限公司 | 改进的基于纤连蛋白的结合分子及其用途 |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014015027A1 (en) * | 2012-07-18 | 2014-01-23 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| TWI897843B (zh) * | 2017-05-03 | 2025-09-21 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
| US11173805B2 (en) * | 2018-01-30 | 2021-11-16 | Karma Automotive Llc | State-of-charge display system |
-
2018
- 2018-05-02 TW TW107114893A patent/TWI897843B/zh active
- 2018-05-03 CN CN201880029635.0A patent/CN110621302A/zh active Pending
- 2018-05-03 JP JP2019560087A patent/JP7157082B2/ja active Active
- 2018-05-03 KR KR1020247022666A patent/KR102838263B1/ko active Active
- 2018-05-03 IL IL270233A patent/IL270233B2/en unknown
- 2018-05-03 AU AU2018261154A patent/AU2018261154B2/en active Active
- 2018-05-03 CA CA3062797A patent/CA3062797A1/en active Pending
- 2018-05-03 SG SG11201909709S patent/SG11201909709SA/en unknown
- 2018-05-03 KR KR1020197035212A patent/KR102683806B1/ko active Active
- 2018-05-03 MX MX2019012506A patent/MX2019012506A/es unknown
- 2018-05-03 EP EP18726649.9A patent/EP3618809A1/en active Pending
- 2018-05-03 US US16/607,688 patent/US20200129595A1/en not_active Abandoned
- 2018-05-03 IL IL305625A patent/IL305625B2/en unknown
- 2018-05-03 WO PCT/US2018/030851 patent/WO2018204617A1/en not_active Ceased
-
2022
- 2022-10-06 JP JP2022161758A patent/JP7442595B2/ja active Active
-
2024
- 2024-07-16 AU AU2024204870A patent/AU2024204870B2/en active Active
-
2025
- 2025-04-30 US US19/194,765 patent/US20260069662A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102007145A (zh) * | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| CN102099373A (zh) * | 2008-05-22 | 2011-06-15 | 百时美施贵宝公司 | 基于纤连蛋白的多价支架结构域蛋白 |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| CN102762591A (zh) * | 2010-02-18 | 2012-10-31 | 百时美施贵宝公司 | 结合il-23的基于纤连蛋白的支架结构域蛋白质 |
| CN103180339A (zh) * | 2010-05-26 | 2013-06-26 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
| CN104768969A (zh) * | 2012-09-13 | 2015-07-08 | 百时美施贵宝公司 | 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020518603A (ja) | 2020-06-25 |
| KR20240113600A (ko) | 2024-07-22 |
| IL270233A (cg-RX-API-DMAC7.html) | 2019-12-31 |
| WO2018204617A8 (en) | 2019-01-03 |
| AU2024204870A1 (en) | 2024-08-01 |
| IL305625B1 (en) | 2024-09-01 |
| JP2023011601A (ja) | 2023-01-24 |
| US20260069662A1 (en) | 2026-03-12 |
| JP7157082B2 (ja) | 2022-10-19 |
| CA3062797A1 (en) | 2018-11-08 |
| TWI897843B (zh) | 2025-09-21 |
| AU2018261154A1 (en) | 2019-11-07 |
| AU2018261154B2 (en) | 2024-05-02 |
| EP3618809A1 (en) | 2020-03-11 |
| MX2019012506A (es) | 2019-12-19 |
| KR20200003076A (ko) | 2020-01-08 |
| JP7442595B2 (ja) | 2024-03-04 |
| AU2024204870B2 (en) | 2026-08-06 |
| IL270233B2 (en) | 2024-02-01 |
| WO2018204617A1 (en) | 2018-11-08 |
| IL270233B1 (en) | 2023-10-01 |
| US20200129595A1 (en) | 2020-04-30 |
| IL305625A (en) | 2023-11-01 |
| TW201842929A (zh) | 2018-12-16 |
| IL305625B2 (en) | 2025-01-01 |
| KR102683806B1 (ko) | 2024-07-11 |
| SG11201909709SA (en) | 2019-11-28 |
| KR102838263B1 (ko) | 2025-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442595B2 (ja) | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 | |
| TWI548424B (zh) | 依那西普之安定的液體調配劑 | |
| US12350340B2 (en) | Viscosity reduction of highly concentrated protein formulations | |
| JP7580404B2 (ja) | Glp1/2二重アゴニストの非経口医薬組成物 | |
| KR102568272B1 (ko) | Glp-1r 항체 융합 단백질의 안정한 약제학적 용액 제형 | |
| TW202432577A (zh) | 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀 | |
| HK40017219A (en) | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin | |
| EP4306103B1 (en) | Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor | |
| RU2815643C2 (ru) | Фармацевтическая парентеральная композиция двойного агониста glp1/2 | |
| RU2828220C2 (ru) | Фармацевтическая парентеральная композиция двойного агониста glp1/2 | |
| WO2025177263A1 (en) | Myostatin-binding proteins | |
| EP2606908A1 (en) | Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40017219 Country of ref document: HK |